Regorafenib for metastatic colorectal cancer

The Lancet

Volumn 381, Issue 9877, 2013, Pages 1537-1538

  Hyun, Myung Han ^a   Shin, Mi Ran ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PLACEBO; REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CODON; GENE MUTATION; HUMAN; LETTER; METASTATIC COLORECTAL CANCER; ONCOGENE N RAS; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; COLORECTAL TUMOR; FEMALE; MALE; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84877291709     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60977-0     Document Type: Letter

References (5)

1. A Grothey, E Van Cutsem, A Sobrero et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
2. SM Wilhelm, J Dumas, L Adnane et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
3. CS Karapetis, S Khambata-Ford, DJ Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
4. JL Bos, ER Fearon, SR Hamilton et al. Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297 (Pubitemid 17075079)
5. W De Roock, DJ Jonker, F Di Nicolantonio et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820